ST
AKBA icon

Spot Trading’s Akebia Therapeutics AKBA Stock Holding History

Spot Trading’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-10,000
Closed -$75K – 3022
2016
Q2 		$75K Sell
10,000
-15,000
-60% -$131K ﹤0.01% 2630
2016
Q1 		$225K Buy
+25,000
New +$203K ﹤0.01% 2132

Other funds holding AKBA

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Spot Trading's AKBA Position: Q4 2016 in Review

Spot Trading sold out of Akebia Therapeutics (AKBA) in Q4 2016, closing a stake of 5,864 shares — an estimated $53K sold.

Spot Trading first reported a position in AKBA in Q2 2016 and held it in 2 quarters. The position peaked at $53K in Q3 2016. 94 funds tracked by Wall St. Rank hold AKBA as of Q4 2016.

  • Spot Trading reported no remaining Akebia Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Spot Trading sold 5,864 Akebia Therapeutics shares in Q4 2016, an estimated $53K.
  • Spot Trading first reported a position in Akebia Therapeutics in Q2 2016 and held it in 2 quarters.
  • Spot Trading's Akebia Therapeutics position peaked at $53K in Q3 2016.
  • 94 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2016.

Based on Spot Trading's 13F filing for Q4 2016, filed 7 Feb 2017.